Over the last twenty years, many studies have analysed the presence of the SPANX-A/D subfamily in various cancers, such as breast, myeloma, haematological, melanoma, bladder and prostate carcinomas3,8–12, to clarify the function of the protein subfamily in carcinogenesis. This evidence concerns the gene SPANXA1 and plasma cell myeloma.